Primary bilateral macronodular adrenal hyperplasia (PBMAH) is an adrenal cause of Cushing syndrome. Nowadays, a PBMAH diagnosis is more frequent than previously, as a result of progress in the diagnostic methods for adrenal incidentalomas, which are widely available. Although some rare syndromic forms of PBMAH are known to be of genetic origin, non-syndromic forms of PBMAH have only been recognized as a genetic disease in the past 10 years. Genomics studies have highlighted the molecular heterogeneity of PBMAH and identified molecular subgroups, allowing improved understanding of the clinical heterogeneity of this disease. Furthermore, the generation of these subgroups permitted the identification of new genes responsible for PBMAH. Constitutive inactivating variants in ARMC5 and KDM1A are responsible for the development of distinct forms of PBMAH. To date, pathogenic variants of ARMC5 are responsible for 20–25% of PBMAH, whereas germline KDM1A alterations have been identified in >90% of PBMAH causing food-dependent Cushing syndrome. The identification of pathogenic variants in ARMC5 and KDM1A demonstrated that PBMAH, despite mostly being diagnosed in adults aged 45–60 years, is a genetic disorder. This Review summarizes the important progress made in the past 10 years in understanding the genetics of PBMAH, which have led to a better understanding of the pathophysiology, opening new clinical perspectives.
Primary bilateral macronodular adrenal hyperplasia (PBMAH) can be diagnosed after the investigation of clinical signs of cortisol excess or bilateral adrenal incidentalomas; multiple bilateral nodules of >1 cm are seen on imaging.
Despite the presentation being apparently sporadic rather than familial, PBMAH is frequently of genetic origin.
Biallelic ARMC5 inactivation is responsible for about 20% of PBMAH and is associated with more severe Cushing syndrome and a high number of macronodules on CT scan in the index patients, compared with other forms of PBMAH.
Biallelic KDM1A inactivation induces a particular form of PBMAH called food-dependent Cushing syndrome that is molecularly characterized by ectopic expression of GIP receptor in adrenocortical cells.
The discovery of ARMC5 and KDM1A genetic alterations in PBMAH enabled familial screening, which can reduce the long-term consequences of cortisol dysregulation as a result of earlier diagnosis.
ARMC5 and KDM1A genetic alterations are not observed in all patients with PBMAH, leading to the view that further research will identify other genetic causes of PBMAH.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Xing, Y., Lerario, A. M., Rainey, W. & Hammer, G. D. Development of adrenal cortex zonation. Endocrinol. Metab. Clin. North. Am. 44, 243–274 (2015).
Pignatti, E., Leng, S., Carlone, D. L. & Breault, D. T. Regulation of zonation and homeostasis in the adrenal cortex. Mol. Cell Endocrinol. 441, 146–155 (2017).
Lyraki, R. & Schedl, A. Adrenal cortex renewal in health and disease. Nat. Rev. Endocrinol. 17, 421–434 (2021).
Lam, K. Y., Chan, A. C. & Lo, C. Y. Morphological analysis of adrenal glands: a prospective analysis. Endocr. Pathol. 12, 33–38 (2001).
van Haalen, F. M., Broersen, L. H., Jorgensen, J. O., Pereira, A. M. & Dekkers, O. M. Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R143–R149 (2015).
Pivonello, R. et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611–629 (2016).
Webb, S. M. & Valassi, E. Morbidity of Cushing’s syndrome and impact of treatment. Endocrinol. Metab. Clin. North. Am. 47, 299–311 (2018).
Fleseriu, M. et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847–875 (2021).
Newell-Price, J., Bertagna, X., Grossman, A. B. & Nieman, L. K. Cushing’s syndrome. Lancet 367, 1605–1617 (2006).
Lacroix, A. ACTH-independent macronodular adrenal hyperplasia. Best. Pract. Res. Clin. Endocrinol. Metab. 23, 245–259 (2009).
Newell-Price, J. Cushing’s syndrome. Clin. Med. 8, 204–208 (2008).
Vassiliadi, D. A. & Tsagarakis, S. Diagnosis and management of primary bilateral macronodular adrenal hyperplasia. Endocr. Relat. Cancer 26, R567–R581 (2019).
Kirschner, M. A., Powell, R. D. Jr. & Lipsett, M. B. Cushing’s syndrome: nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J. Clin. Endocrinol. Metab. 24, 947–955 (1964).
Lieberman, S. A., Eccleshall, T. R. & Feldman, D. ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing’s syndrome with major diagnostic and therapeutic implications. Eur. J. Endocrinol. 131, 67–73 (1994).
Strohm, M., Reincke, M., Theiss, M., Diehl, K. L. & Allolio, B. Bilateral massive macronodular adrenal gland hyperplasia. A rare cause of Cushing’s syndrome [German]. Dtsch. Med. Wochenschr. 119, 180–184 (1994).
Cugini, P. et al. “GIANT” macronodular adrenal hyperplasia causing Cushing’s syndrome: case report and review of the literature on a clinical distinction of adrenocortical nodular pathology associated with hypercortisolism. Endocrinol. Jpn. 36, 101–116 (1989).
Aiba, M. Cushing’s syndrome due to huge bilateral adrenocortical multinodular hyperplasia–ACTH-independent bilateral adrenocortical macronodular hyperplasia (AIMAH) [Japanese]. Nihon Naibunpi Gakkai Zasshi 70, 37–42 (1994).
Faucz, F. R. et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J. Clin. Endocrinol. Metab. 99, E1113–E1119 (2014).
Lefebvre, H., Duparc, C., Prevost, G., Bertherat, J. & Louiset, E. Cell-to-cell communication in bilateral macronodular adrenal hyperplasia causing hypercortisolism. Front. Endocrinol. 6, 34 (2015).
Alencar, G. A. et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1501–E1509 (2014). In this article, the authors describe the first large family with ARMC5 pathogenic variants, with 16 carriers all affected by PBMAH.
Louiset, E. et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2115–2125 (2013).
Lacroix, A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2147–2149 (2013).
Findlay, J. C., Sheeler, L. R., Engeland, W. C. & Aron, D. C. Familial adrenocorticotropin-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 76, 189–191 (1993).
Gagliardi, L. et al. Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindreds. Clin. Endocrinol. 70, 883–891 (2009).
Vezzosi, D. et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur. J. Endocrinol. 156, 21–31 (2007).
Lee, S. et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin. Endocrinol. 63, 625–630 (2005).
Assie, G. et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N. Engl. J. Med. 369, 2105–2114 (2013). This is the first paper demonstrating the biallelic loss of ARMC5 in PBMAH tissues by combining SNP array and whole-exosome sequencing.
Vaczlavik, A. et al. KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genet. Med. 24, 374–383 (2022). This article uncovers the molecular heterogeneity existing between PBMAH tissues, leading to the discovery of biallelic KDM1A inactivation.
Chasseloup, F. et al. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol. 9, 813–824 (2021). This article demonstrates the role of KDM1A inactivation in PBMAH associated with the development of food-dependent Cushing syndrome.
Mete, O. et al. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr. Pathol. 33, 155–196 (2022).
Fassnacht, M. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175, G1–G34 (2016).
Barzon, L. et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J. Clin. Endocrinol. Metab. 83, 55–62 (1998).
Bourdeau, I., El Ghorayeb, N., Gagnon, N. & Lacroix, A. Management of endocrine disease: differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur. J. Endocrinol. 179, R57–R67 (2018).
Candida Barisson Villares Fragoso, M., Pontes Cavalcante, I., Meneses Ferreira, A., Marinho de Paula Mariani, B. & Ferini Pacicco Lotfi, C. Genetics of primary macronodular adrenal hyperplasia. Presse Med. 47, e139–e149 (2018).
Espiard, S. et al. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. J. Clin. Endocrinol. Metab. 100, E926–E935 (2015).
Zhou, J. et al. Demographic characteristics, etiology, and comorbidities of patients with Cushing’s syndrome: a 10-year retrospective study at a large general hospital in China. Int. J. Endocrinol. 2019, 7159696 (2019).
Bouys, L. et al. Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients. Eur. J. Endocrinol. 187, 123–134 (2022).
Bouys, L., Chiodini, I., Arlt, W., Reincke, M. & Bertherat, J. Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). Endocrine 71, 595–603 (2021).
Di Dalmazi, G. et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2, 396–405 (2014).
Debono, M. et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99, 4462–4470 (2014).
Kjellbom, A., Lindgren, O., Puvaneswaralingam, S., Londahl, M. & Olsen, H. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann. Intern. Med. 174, 1041–1049 (2021).
Prete, A. et al. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multicenter study. Ann. Intern. Med. 175, 325–334 (2022).
St-Jean, M., Ghorayeb, N. E., Bourdeau, I. & Lacroix, A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best. Pract. Res. Clin. Endocrinol. Metab. 32, 165–187 (2018).
Albiger, N. M. et al. An analysis of different therapeutic options in patients with Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin. Endocrinol. 82, 808–815 (2015).
Sasano, H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr. J. 41, 471–482 (1994).
Faillot, S. et al. Genomic classification of benign adrenocortical lesions. Endocr. Relat. Cancer 28, 79–95 (2021). This article demonstrates the specific transcriptomic signature of PBMAH compared with other cortisol-producing adrenal lesions, such as PPNAD and adrenocortical adenomas, demonstrating its uniqueness.
Barreau, O. et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. J. Clin. Endocrinol. Metab. 97, E301–E311 (2012).
Assie, G. et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 (2014).
Bourdeau, I. et al. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 23, 1575–1585 (2004).
Gagliardi, L. et al. Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia. Endocr. Relat. Cancer 19, L19–L23 (2012).
Almeida, M. Q. et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J. Clin. Endocrinol. Metab. 97, E687–E693 (2012).
Berthon, A., Hannah-Shmouni, F., Maria, A. G., Faucz, F. R. & Stratakis, C. A. High expression of adrenal P450 aromatase (CYP19A1) in association with ARMC5-primary bilateral macronodular adrenocortical hyperplasia. J. Steroid Biochem. Mol. Biol. 191, 105316 (2019).
Agarwal, S. K. Multiple endocrine neoplasia type 1. Front. Horm. Res. 41, 1–15 (2013).
Gatta-Cherifi, B. et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166, 269–279 (2012).
Langer, P. et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J. Surg. 26, 891–896 (2002).
Waldmann, J. et al. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch. Surg. 392, 437–443 (2007).
Bodmer, W. F. et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328, 614–616 (1987).
Leppert, M. et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 238, 1411–1413 (1987).
Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B. & Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl Acad. Sci. USA 92, 3046–3050 (1995).
Rowley, P. T. Inherited susceptibility to colorectal cancer. Annu. Rev. Med. 56, 539–554 (2005).
Cetta, F. et al. Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J. Clin. Endocrinol. Metab. 86, 427–432 (2001).
Gaujoux, S. et al. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin. Cancer Res. 16, 5133–5141 (2010).
Hsiao, H. P. et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J. Clin. Endocrinol. Metab. 94, 2930–2937 (2009).
Marchesa, P., Fazio, V. W., Church, J. M. & McGannon, E. Adrenal masses in patients with familial adenomatous polyposis. Dis. Colon Rectum 40, 1023–1028 (1997).
Weinstein, L. S., Liu, J., Sakamoto, A., Xie, T. & Chen, M. Minireview: GNAS: normal and abnormal functions. Endocrinology 145, 5459–5464 (2004).
Dumitrescu, C. E. & Collins, M. T. McCune-Albright syndrome. Orphanet J. Rare Dis. 3, 12 (2008).
Carney, J. A., Young, W. F. & Stratakis, C. A. Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome. Am. J. Surg. Pathol. 35, 1311–1326 (2011).
Fragoso, M. C. et al. Cushing’s syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J. Clin. Endocrinol. Metab. 88, 2147–2151 (2003).
Sudarshan, S., Pinto, P. A., Neckers, L. & Linehan, W. M. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer – a distinct form of hereditary kidney cancer. Nat. Clin. Pract. Urol. 4, 104–110 (2007).
Matyakhina, L. et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: a clinical and molecular genetic investigation. J. Clin. Endocrinol. Metab. 90, 3773–3779 (2005).
Lehtonen, H. J. et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43, 523–526 (2006).
Soberg, K., Moen, L. V., Skalhegg, B. S. & Laerdahl, J. K. Evolution of the cAMP-dependent protein kinase (PKA) catalytic subunit isoforms. PLoS ONE 12, e0181091 (2017).
Lacroix, A. et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin. Endocrinol. 73, 1–15 (2010).
Mazzuco, T. L., Chabre, O., Feige, J. J. & Thomas, M. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing’s syndrome features. J. Clin. Endocrinol. Metab. 91, 196–203 (2006).
Pralong, F. P. et al. Food-dependent Cushing’s syndrome: possible involvement of leptin in cortisol hypersecretion. J. Clin. Endocrinol. Metab. 84, 3817–3822 (1999).
Cartier, D. et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing’s syndrome. J. Clin. Endocrinol. Metab. 88, 248–254 (2003).
Louiset, E. et al. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing’s syndrome: molecular, immunohistochemical and pharmacological correlates. J. Endocrinol. 196, 1–9 (2008).
Lacroix, A., Tremblay, J., Rousseau, G., Bouvier, M. & Hamet, P. Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing’s syndrome. N. Engl. J. Med. 337, 1429–1434 (1997).
Louiset, E. et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing’s syndrome. J. Clin. Endocrinol. Metab. 91, 4578–4586 (2006).
Lacroix, A. et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion – a new cause of Cushing’s syndrome. N. Engl. J. Med. 327, 974–980 (1992).
Reznik, Y. et al. Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N. Engl. J. Med. 327, 981–986 (1992).
Pitsava, G. & Stratakis, C. A. Genetic alterations in benign adrenal tumors. Biomedicines 10, 1041 (2022).
Swords, F. M. et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol. Endocrinol. 16, 2746–2753 (2002).
Swords, F. M., Noon, L. A., King, P. J. & Clark, A. J. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Mol. Cell Endocrinol. 213, 149–154 (2004).
Hiroi, N. et al. Human ACTH hypersensitivity syndrome associated with abnormalities of the ACTH receptor gene. Clin. Endocrinol. 48, 129–134 (1998).
Beuschlein, F. et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N. Engl. J. Med. 370, 1019–1028 (2014).
Carney, J. A., Lyssikatos, C., Lodish, M. B. & Stratakis, C. A. Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes. Hum. Pathol. 46, 40–49 (2015).
Lodish, M. B. et al. Germline PRKACA amplification causes variable phenotypes that may depend on the extent of the genomic defect: molecular mechanisms and clinical presentations. Eur. J. Endocrinol. 172, 803–811 (2015).
Hannah-Shmouni, F., Faucz, F. R. & Stratakis, C. A. Alterations of phosphodiesterases in adrenocortical tumors. Front. Endocrinol. 7, 111 (2016).
Rothenbuhler, A. et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin. Endocrinol. 77, 195–199 (2012).
Libe, R. et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin. Cancer Res. 14, 4016–4024 (2008).
Vezzosi, D. et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J. Clin. Endocrinol. Metab. 97, E2063–E2069 (2012).
Correa, R. et al. The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. Eur. J. Endocrinol. 173, 435–440 (2015).
Elbelt, U. et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J. Clin. Endocrinol. Metab. 100, E119–E128 (2015).
Albiger, N. M. et al. A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine 55, 959–968 (2017).
Gagliardi, L. et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1784–E1792 (2014).
Bourdeau, I. et al. ARMC5 mutations in a large French–Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. Eur. J. Endocrinol. 174, 85–96 (2016).
Yu, L. et al. ARMC5 mutations in familial and sporadic primary bilateral macronodular adrenal hyperplasia. PLoS ONE 13, e0191602 (2018).
Rego, T. et al. ARMC5 mutation in a Portuguese family with primary bilateral macronodular adrenal hyperplasia (PBMAH). Endocrinol. Diabetes Metab. Case Rep. 2017, 16-0135 (2017).
Suzuki, S. et al. Germline deletion of Armc5 in familial primary macronodular adrenal hyperplasia. Endocr. Pract. 21, 1152–1160 (2015).
Stratakis, C. A. & Berthon, A. Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology. Curr. Opin. Endocr. Metab. Res. 8, 104–111 (2019).
Kyo, C. et al. ARMC5 alterations in primary macronodular adrenal hyperplasia (PMAH) and the clinical state of variant carriers. J. Endocr. Soc. 3, 1837–1846 (2019).
Zhang, F., Lin, X. & Yu, X. Primary macronodular adrenal hyperplasia (PMAH) can be generated by a new ARMC5 germline variant (c.52C>T (p.Gln18X)). Endocr. J. 67, 1179–1186 (2020).
Drougat, L., Omeiri, H., Lefevre, L. & Ragazzon, B. Novel insights into the genetics and pathophysiology of adrenocortical tumors. Front. Endocrinol. 6, 96 (2015).
Cavalcante, I. P. et al. The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH). Mol. Cell Endocrinol. 460, 36–46 (2018).
Pintard, L., Willems, A. & Peter, M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J. 23, 1681–1687 (2004).
Hu, Y. et al. Armc5 deletion causes developmental defects and compromises T-cell immune responses. Nat. Commun. 8, 13834 (2017).
Cavalcante, I. P. et al. Cullin 3 targets the tumor suppressor gene ARMC5 for ubiquitination and degradation. Endocr. Relat. Cancer 27, 221–230 (2020).
Wilkins, A., Ping, Q. & Carpenter, C. L. RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex. Genes Dev. 18, 856–861 (2004).
Zhou, Z. et al. Stability of HIB-Cul3 E3 ligase adaptor HIB is regulated by self-degradation and availability of its substrates. Sci. Rep. 5, 12709 (2015).
Berthon, A. et al. Age-dependent effects of Armc5 haploinsufficiency on adrenocortical function. Hum. Mol. Genet. 26, 3495–3507 (2017).
Groussin, L. et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J. Clin. Endocrinol. Metab. 87, 1980–1985 (2002).
Bertherat, J. et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing’s syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 90, 1302–1310 (2005).
Lecoq, A. L. et al. Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing’s syndrome. JCI Insight 2, e92184 (2017).
Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).
Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480–488 (2013).
Lan, F., Nottke, A. C. & Shi, Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr. Opin. Cell Biol. 20, 316–325 (2008).
Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436–439 (2005).
Shao, G. et al. Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells. Oncol. Lett. 15, 9025–9032 (2018).
Fang, R., Xu, J., Lin, H., Xu, X. & Tian, F. The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion. Tumour Biol. 39, 1010428317698356 (2017).
Zhu, D. et al. Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells. Nat. Commun. 5, 3174 (2014).
Clark, E. A. et al. GR and LSD1/KDM1A-targeted gene activation requires selective H3K4me2 demethylation at enhancers. Cell Rep. 27, 3522–3532 (2019).
Bennesch, M. A., Segala, G., Wider, D. & Picard, D. LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP. Nucleic Acids Res. 44, 8655–8670 (2016).
Whyte, W. A. et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482, 221–225 (2012).
Lacroix, A., Hamet, P. & Boutin, J. M. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing’s syndrome. N. Engl. J. Med. 341, 1577–1581 (1999).
Jojima, T. et al. Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. Eur. J. Endocrinol. 183, K7–K12 (2020).
Wei, X. et al. Germline lysine-specific demethylase 1 (LSD1/KDM1A) mutations confer susceptibility to multiple myeloma. Cancer Res. 78, 2747–2759 (2018).
Ferreira, M. J. et al. ARMC5 primary bilateral macronodular adrenal hyperplasia associated with a meningioma: a family report. Case Rep. Endocrinol. 2020, 8848151 (2020).
Shiroky, J. S., Lerner-Ellis, J. P., Govindarajan, A., Urbach, D. R. & Devon, K. M. Characteristics of adrenal masses in familial adenomatous polyposis. Dis. Colon Rectum 61, 679–685 (2018).
Brown, R. J., Kelly, M. H. & Collins, M. T. Cushing syndrome in the McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 95, 1508–1515 (2010).
Shuch, B. et al. Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J. Urol. 189, 430–435 (2013).
The authors thank L. Bouys and E. Pasmant from Institut Cochin (Université Paris Cité, Inserm U1016, CNRS UMR8104, Paris, France) for helpful discussions. J.B.’s laboratory was supported by the Agence Nationale de la Recherche (18-CE14-0008-01; ANR-21-CE14-0011-01) and the Fondation pour la Recherche Médicale (FRM EQU201903007854). M.C.F. and J.B. received funding from FAPESP-ANR (#2015/50192-9). M.R. was supported by a grant from the Else Kröner-Fresenius Stiftung (2012_A103 and 2015_A228) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Projektnummer 314061271-TRR 205). I.P.C. receives a fellowship from the Fondation pour la Recherche Médicale (SPF201809007096).
J.B. has received grants to his institution from Novartis, HRA Pharma and Recordati, and personal honoraria for consulting, lectures and meeting attendance from Novartis, Corcept, HRA Pharma and Recordati. C.A.S. holds patents on PRKAR1A, PDE11A and GPR101 function; he has also received support from ELPEN, Pfizer, Sandoz and Lundbeck pharmaceuticals. M.R. has received personal honoraria for consulting, lectures and advisory board membership from Novartis, Recordati, HRA Pharma, Crinetics and Ipsen. The other authors declare no competing interests.
Peer review information
Nature Reviews Endocrinology thanks Carla Scaroni, who co-reviewed with Filippo Ceccato, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cavalcante, I.P., Berthon, A., Fragoso, M.C. et al. Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease. Nat Rev Endocrinol (2022). https://doi.org/10.1038/s41574-022-00718-y